Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction

American Journal of Cardiology

Volumn 78, Issue 5, 1996, Pages 503-510

  Scharfstein, Jonathan S ^b   Abendschein, Dana R ^b   Eisenberg, Paul R ^b   George, Dorinda ^b   Cannon, Christopher P ^b   Becker, Richard C ^b   Sobel, Burton ^b   Cupples, L Adrienne ^b   Braunwald, Eugene ^b   Loscalzo, Joseph ^a  

^a BOSTON MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; ANTITHROMBIN III PROTEASE COMPLEX; ANTITHROMBIN III-PROTEASE COMPLEX; BIOLOGICAL MARKER; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN BBETA (15 42); FIBRINOGEN BBETA (15-42); FIBRINOLYTIC AGENT; FIBRINOPEPTIDE A; HEPARIN; PEPTIDE FRAGMENT; PEPTIDE HYDROLASE; PROTHROMBIN; PROTHROMBIN FRAGMENT 1.2; RECOMBINANT PROTEIN;

ANTICOAGULANT THERAPY; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEMOSTASIS; HUMAN; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTITHROMBIN III; BIOLOGICAL MARKERS; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYTIC AGENTS; FIBRINOPEPTIDE A; HEMOSTASIS; HEPARIN; HIRUDIN THERAPY; HUMANS; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; PEPTIDE HYDROLASES; PILOT PROJECTS; PROTHROMBIN; RECOMBINANT PROTEINS; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 10644275408     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(96)00353-0     Document Type: Article

References (20)

1. Eisenberg PR, Sherman LA, Rich M, Schwartz D, Schechtman K, Geltman EM, Sobel BE, Jaffe AS. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. J Am Coll Cardiol 1986;7:1255-1262.
2. Rapold HJ, Grimaudo V, Declerck PJ, Kruithof EK, Bachmann F. Plasma levels of plasminogen activator inhibitor type 1, beta-thromboglobulin, and fibrinopeptide A before, during, and after treatment of acute myocardial infarction with alteplase. Blood 1991;78:1490-1495.
3. Rapold HJ, de Bono D, Arnold AE, Arnout J, DeCock F, Collen D, Verstraete M. Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase. Correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. The European Cooperative Study Group. Circulation 1992;85:928-934.
4. Rapold HJ, Kuemmerli H, Weiss M, Baur H, Haeberli A. Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator. Circulation 1989;79:980-989.
5. Ring ME, Butman SM, Bruck DC, Feinberg WM, Corrigan JJ. Fibrin metabolism in patients with acute myocardial infarction during and after treatment with tissue-type plasminogen activator. Thromb Haemost 1988;60:428-433.
6. Eisenberg PR, Sherman LA, Jaffe AS. Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense thrombolysis. J Am Coll Cardiol 1987;10:527-529.
7. Owen J, Friedman BA, Wilkins C, Berke AD, Powers ER. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood 1988;72:616-620.
8. GUSTO Angiographic Investigators. The comparative effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-1622.
9. Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, Becker RC, Kleiman NS, Haughland JM, Anderson JL, Sharaf BL, Edwards SJ, Rogers WJ, Williams DO, Braunwauld E, for the TIMI Investigators. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 Trial. J Am Coll Cardiol 1994;23:993-1003.
10. Kockum C, Frebelius S. Rapid immunoassay of human fibrinopeptide A - removal of cross-reacting fibrinogen with bentonite. Thromb Res 1980;19:589-598.
11. Eisenberg PR, Sherman LA, Schectman K, Perez J, Sobel BE, Jaffe AS. Fibrinopeptide A: a marker of acute coronary thrombosis. Circulation 1985;71:912-918.
12. Hursting MJ, Butman BT, Steiner JP, Moore BM, Plank MC, Szewczyk KM, Bell ML, Dombrose FA. Monoclonal antibodies specific for prothrombin fragment 1.2 and their use in a quantitative enzyme-linked immunosorbent assay. Clin Chem 1993;39:583-591.
13. Hursting MJ, Stead AG, Crout FV, Horvath BZ, Moore BM. Effects of age, race, sex, and smoking on prothrombin fragment 1.2 in a healthy population. Clin Chem 1993;39:683-686.
14. Pelzer H, Schwarz A, Heimburger N. Determination of human thrombinantithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1988;59:101-106.
15. 2-terminal fragments derived from fibrinogen and fibrin. Mol Immunol 1983;20:1191-1200.
16. Lawler CM, Bovill EG, Stump DC, Collen DJ, Mann KG, Tracy RP. Fibrin fragment D-dimer and fibrinogen B beta peptides in plasma as markers of clot lysis during thrombolytic therapy in acute myocardial infarction. Blood 1990;76:1341-1348.
17. Lincoff AM, Ellis SG, Galeana A, Sigmon KN, Lee KL, Rosenschein U, for the AMI Study Group. Is a coronary artery with TIMI grade 2 flow "patent"? Outcome in the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Trial (abstr). Circulation 1992;86(suppl I):I-268.
18. Vogt A, Von Essen R, Tebbe U, Feuerer W, Appel K-F, Neuhaus K-L. Impact of early reperfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies. J Am Coll Cardiol 1993;21:1391-1395.
19. Ewald GA, Eisenberg PR. Plasmin-mediated activation of the contact system in response to pharmacological thrombolysis. Circulation 1995;91: 28-36.
20. Niewiarowski S, Budzynski AZ, Lipinski B. Significance of the intact polypeptide chains of human fibrinogen in ADP-induced platelet aggregation. Blood 1977;49:535-544.